AKBLF ALK-Abelló A/S

USD 18.40 0.00 0
Icon

ALK-Abelló A/S (AKBLF) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 18.40

0.00 (0.00)%

USD 4.27B

N/A

N/A

N/A

Icon

AKBLF

ALK-Abelló A/S (USD)
COMMON STOCK | OTC
USD 18.40
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 4.27B

N/A

USD 18.40

ALK-Abelló A/S (AKBLF) Stock Forecast

N/A

Based on the ALK-Abelló A/S stock forecast from 0 analysts, the average analyst target price for ALK-Abelló A/S is not available over the next 12 months. ALK-Abelló A/S’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ALK-Abelló A/S is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, ALK-Abelló A/S’s stock price was USD 18.40. ALK-Abelló A/S’s stock price has changed by -0.54% over the past week, -0.54% over the past month and +31.43% over the last year.

No recent analyst target price found for ALK-Abelló A/S
No recent average analyst rating found for ALK-Abelló A/S

Company Overview ALK-Abelló A/S

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic a...Read More

https://www.alk.net

Bøge Allé 6-8, Horsholm, Denmark, 2970

2,824

December

USD

USA

Adjusted Closing Price for ALK-Abelló A/S (AKBLF)

Loading...

Unadjusted Closing Price for ALK-Abelló A/S (AKBLF)

Loading...

Share Trading Volume for ALK-Abelló A/S Shares

Loading...

Compare Performance of ALK-Abelló A/S Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AKBLF

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To ALK-Abelló A/S (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S -0.95 (-0.75%) USD599.92B 48.04 5.17

ETFs Containing AKBLF

Symbol Name AKBLF's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About ALK-Abelló A/S (AKBLF) Stock

Stock Target Advisor's fundamental analysis for ALK-Abelló A/S's stock is Slightly Bullish .

Unfortunately we do not have enough data on AKBLF's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AKBLF's stock to indicate what its average analyst target is.

AKBLF stock's Price/Earning ratio is 57.81. Our analysis grades AKBLF stock's Price / Earning ratio at F. This means that AKBLF stock's Price/Earning ratio is above 78% of the stocks in the Biotechnology sector in the OTC exchange. Based on this AKBLF may be a overvalued for its sector.

The last closing price of AKBLF's stock was USD 18.40.

The most recent market capitalization for AKBLF is USD 4.27B.

Unfortunately we do not have enough analyst data on AKBLF's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains ALK-Abelló A/S's stock.

As per our most recent records ALK-Abelló A/S has 2,824 Employees.

ALK-Abelló A/S's registered address is Bøge Allé 6-8, Horsholm, Denmark, 2970. You can get more information about it from ALK-Abelló A/S's website at https://www.alk.net.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...